Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug 14:10:1038.
doi: 10.3389/fphys.2019.01038. eCollection 2019.

Role of the Extracellular Signal-Regulated Kinase 1/2 Signaling Pathway in Ischemia-Reperfusion Injury

Affiliations
Review

Role of the Extracellular Signal-Regulated Kinase 1/2 Signaling Pathway in Ischemia-Reperfusion Injury

Tingting Kong et al. Front Physiol. .

Abstract

Extracellular signal-regulated kinase 1/2 (ERK1/2), an important member of the mitogen-activated protein kinase family, is found in many organisms, and it participates in intracellular signal transduction. Various stimuli induce phosphorylation of ERK1/2 in vivo and in vitro. Phosphorylated ERK1/2 moves to the nucleus, activates many transcription factors, regulates gene expression, and controls various physiological processes, finally inducing repair processes or cell death. With the aging of the population around the world, the occurrence of ischemia-reperfusion injury (IRI), especially in the brain, heart, kidney, and other important organs, is becoming increasingly serious. Abnormal activation of the ERK1/2 signaling pathway is closely related to the development and the metabolic mechanisms of IRI. However, the effects of this signaling pathway and the underlying mechanism differ between various models of IRI. This review summarizes the ERK1/2 signaling pathway and the molecular mechanism underlying its role in models of IRI in the brain, heart, liver, kidneys, and other organs. This information will help to deepen the understanding of ERK1/2 signals and deepen the exploration of IRI treatment based on the ERK1/2 study.

Keywords: ERK1/2 signaling pathway; damage effect; ischemia-reperfusion injury; molecular mechanism; protective effect; therapeutic target.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Summary of the classical Ras-Raf-MEK-ERK1/2 signaling pathway. Extracellular signals stimulate G-protein-coupled receptors (GCPRs), receptor tyrosine kinases (RTKs), and integrins on the membrane, and activate ERK1/2, a key signaling molecule, via a series of cascade reactions. ERK1/2 is usually located in the cytoplasm. Once activated, ERK1/2 rapidly crosses the nuclear membrane, reactivates transcription factors, regulates transcription of target genes, induces expression or activation of specific proteins, and finally regulates cellular metabolism and function.
Figure 2
Figure 2
Summary of the functions of the ERK1/2 signaling pathway. Cytokines regulate cellular processes via the ERK1/2 signaling pathway. Extracellular stimulation leads to phosphorylation of ERK1/2, which affects various cellular activities by mediating activation of transcription factors.
Figure 3
Figure 3
Summary of the role of the ERK1/2 signaling pathway in CIRI. (A) Neuroprotection against CIRI via activation of the ERK1/2 signaling pathway. A few studies reported that activation of the ERK1/2 signaling pathway elicits neuroprotective effects against CIRI. (B) Neuroprotection against CIRI via blockade of the ERK1/2 signaling pathway. Most studies reported that inhibition of the ERK1/2 signaling pathway blocks downstream damage, including inflammation and apoptosis, and thereby protects against CIRI.

Similar articles

Cited by

References

    1. Al-Salam S., Hashmi S. (2018). Myocardial ischemia reperfusion injury: apoptotic, inflammatory and oxidative stress role of galectin-3. Cell. Physiol. Biochem. 50, 1123–1139. 10.1159/000494539, PMID: - DOI - PubMed
    1. Asati V., Mahapatra D. K., Bharti S. K. (2016). Pi3k/akt/mtor and ras/raf/mek/erk signaling pathways inhibitors as anticancer agents: structural and pharmacological perspectives. Eur. J. Med. Chem. 109, 314–341. 10.1016/j.ejmech.2016.01.012, PMID: - DOI - PubMed
    1. Bilzer M., Gerbes A. L. (2000). Preservation injury of the liver: mechanisms and novel therapeutic strategies. J. Hepatol. 32, 508–515. 10.1016/s0168-8278(00)80404-3 - DOI - PubMed
    1. Boilly B., Vercoutteredouart A., Hondermarck H., Nurcombe V., Bourhis X. L. (2000). FGF signals for cell proliferation and migration through different pathways. Cytokine Growth Factor Rev. 11, 295–302. 10.1016/S1359-6101(00)00014-9, PMID: - DOI - PubMed
    1. Bonventre J. V., Zuk A. (2004). Ischemic acute renal failure: an inflammatory disease? Kidney Int. 66, 480–485. 10.1111/j.1523-1755.2004.761_2.x, PMID: - DOI - PubMed